Pfizer leaves investors guessing on intentions for AstraZeneca

July 30th, 2014 Pfizer Inc, which in May abandoned its $118 billion bid for AstraZeneca Plc, on Tuesday left investors guessing whether it would renew its pursuit of its British rival, but said it was considering other deals. The largest U.S. drugmaker reported higher-than-expected second-quarter revenue, helped by growing demand for its cancer medicines. But overall sales fell on competition …

MedImmune and Advaxis partner on immuno-oncology combination clinical trial

July 22, 2014 AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies. The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis’ lead cancer immunotherapy vaccine, ADXS-HPV, …

CDC Advisory Committee Recommends Preferential Use of Live Attenuated Influenza Vaccine (LAIV) for Eligible Children 2 to 8 Years of Age

June 26, 2014 The MedImmune Specialty Care division of AstraZeneca announced that the U.S. Centers for Disease Control & Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) recommended that when available, Live Attenuated Influenza Vaccine (LAIV) should be used for healthy children 2 to 8 years of age, who have no contraindications or precautions. The ACIP’s unanimous vote was based on …

MD Anderson, MedImmune Join Forces to Advance Cancer Immunotherapy

March 13, 2014 The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson’s Moon Shots Program to develop therapies that unleash patients’ immune systems to attack their cancers. “Our collaboration with MedImmune, a leader in the field of immunotherapy, will draw on the strengths of both institutions to …

AstraZeneca quadrivalent flu shot approved in EU

AstraZeneca’s four-strain influenza vaccine, Fluenz Tetra, is the second quadrivalent shot to be approved in the EU, following the decision of the EMA to grant marketing authorisation for the vaccine in children from 2 to 18 years. The EMA’s approval of the nasally-administrated four-strain vaccine follows the approval back in April of GSK’s four-strain Influsplit Tetra (in Germany) / Fluarix …